Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Celldex Therapeutics (CLDX) reported a Q3 loss of $0.64 per share, which was better than the Zacks Consensus Estimate of a $0.69 loss. This is an improvement from the $0.81 loss per share reported a year ago.
November 06, 2024 | 11:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Celldex Therapeutics reported a Q3 loss of $0.64 per share, beating the Zacks Consensus Estimate of a $0.69 loss. This marks an improvement from the previous year's $0.81 loss per share.
The better-than-expected earnings report and improvement from the previous year suggest positive momentum for Celldex Therapeutics. This could lead to a short-term increase in stock price as investors react to the positive earnings surprise.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100